Karen Sims
Chief Tech/Sci/R&D Officer at ARBUTUS BIOPHARMA CORPORATION
Net worth: 341 474 $ as of 2024-04-29
Network origin in Karen Sims first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 31 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Karen Sims via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| GILEAD SCIENCES, INC. | Biotechnology | Corporate Officer/Principal Chief Tech/Sci/R&D Officer Corporate Officer/Principal Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| MERCK & CO., INC. | Pharmaceuticals: Major | Comptroller/Controller/Auditor Corporate Officer/Principal | |
Sumitomo Pharma America, Inc.
 Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Pharmaceuticals: Major | Chief Executive Officer Director of Finance/CFO | |
| WINDTREE THERAPEUTICS, INC. | Pharmaceuticals: Major | Public Communications Contact | |
QVT Financial LP
 QVT Financial LP Investment ManagersFinance QVT Financial LP is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded in 2003 by Daniel Gold. QVT Financial provides administrative and/or investment management services to private funds including US limited partnerships, non-US limited partnerships and non-US Corporation. | Investment Managers | Portfolio Manager-Equities Analyst-Equity | |
Pharmasset, Inc.
 Pharmasset, Inc. Pharmaceuticals: OtherHealth Technology Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ. | Pharmaceuticals: Other | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| POLYMEDIX, INC. | Pharmaceuticals: Major | Investor Relations Contact | |
| MARINUS PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Investor Relations Contact | |
| UNILIFE CORP | Medical Specialties | Director of Finance/CFO Compliance Officer | |
| EUPRAXIA PHARMACEUTICALS INC. | Biotechnology | Director of Finance/CFO | |
Arbutus Biopharma, Inc.
 Arbutus Biopharma, Inc. BiotechnologyHealth Technology Arbutus Biopharma, Inc. engages in the research and development of pharmaceutical products for Hepatitis B. Its operation includes covalently closed circular DNA, Capsid Assembly, Cyclophilins, and Surface Antigen. The company was founded by Patrick T. Higgins, Michael J. Sofia, Michael J. McElhaugh, and Bryce A. Roberts in May 2012 and is headquartered in Doylestown, PA. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member Founder Chief Executive Officer Chief Executive Officer | |
Syntimmune, Inc.
 Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | Biotechnology | Director/Board Member | |
| ROIVANT SCIENCES LTD. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer President | |
| MORPHOSYS AG | Biotechnology | Director/Board Member | |
| Delaware Valley University | College/University | Undergraduate Degree | |
| The Johns Hopkins University | College/University | Undergraduate Degree | |
| University of British Columbia | College/University | Doctorate Degree Undergraduate Degree | |
| Oregon Health & Science University | College/University | Doctorate Degree | |
NIRI Philadelphia Chapter
 NIRI Philadelphia Chapter Miscellaneous Commercial ServicesCommercial Services NIRI Philadelphia Chapter provides investor relations services. It serves corporate management, shareholders, securities analysts and other financial community constituents. The company was founded in1969 and is headquartered in Philadelphia, PA. | Miscellaneous Commercial Services | Director/Board Member | |
Global Virus Network
 Global Virus Network Miscellaneous Commercial ServicesCommercial Services Global Virus Network conducts research on essential and critical defense against viral diseases. The non-profit company is based in Baltimore, MD. The company was founded by William Walmsley Hall and Robert C. Gallo. | Miscellaneous Commercial Services | Director/Board Member | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin | |
Pulmocide Ltd.
 Pulmocide Ltd. Pharmaceuticals: MajorHealth Technology Pulmocide Ltd. provides biopharmaceutical services. It develops inhaled medicines for viral and fungal infections of the respiratory tract. The company was founded by William Garth Rapeport, John Murray, Kazuhiro Ito, and Peter Strong on March 23, 2007 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
| Harvard College | College/University | Undergraduate Degree Undergraduate Degree | |
| Columbia University College of Physicians & Surgeons | College/University | Doctorate Degree | |
Roivant Sciences GmbH
 Roivant Sciences GmbH Pharmaceuticals: MajorHealth Technology Roivant Sciences GmbH engages in the development and marketing of biopharmaceutical products. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Operating Officer | |
Renaissance BioScience Corp.
 Renaissance BioScience Corp. Miscellaneous Commercial ServicesCommercial Services Renaissance BioScience Corp. is a bioengineering private company based in Vancouver, Canada. The Canadian company specializes in microbial bioengineering innovation and develop market-ready, functional microorganisms for various industries such as agriculture, food and beverage, health, and energy. Renaissance BioScience's proprietary strain collections, breeding knowledge, fermentation, and screening platforms are used to engineer and deliver unique, scalable solutions for industry and academia. The company's technologies have created products that impact millions of people worldwide, including acrylamide-reducing yeast for safer foods and H2S-preventing wine yeast. More information about the Renaissance group of companies is available on their website. The company was founded by John Husnik and Maurice Boucher, and John Husnik has been the CEO since incorporation. | Miscellaneous Commercial Services | Director/Board Member | |
| SIO GENE THERAPIES INC. | Pharmaceuticals: Major | Director/Board Member Chairman Chief Executive Officer Director/Board Member | |
Axovant Sciences, Inc.
 Axovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sio Gene Therapies, Inc., Axovant Sciences, Inc. is a company that manufactures and distributes pharmaceutical products. The company is based in New York, NY. | Pharmaceuticals: Major | Chairman Chief Executive Officer | |
Myovant Sciences, Inc.
 Myovant Sciences, Inc. Medical SpecialtiesHealth Technology Myovant Sciences, Inc. offers therapeutics for women's health and prostate cancer. The company is headquartered in New York, NY. | Medical Specialties | President Director/Board Member | |
| MYOVANT SCIENCES LTD. | Biotechnology | Director of Finance/CFO Chairman Director/Board Member Director/Board Member Chairman | |
| NABRIVA THERAPEUTICS PLC | Pharmaceuticals: Major | Chairman Corporate Officer/Principal | |
Dermavant Sciences, Inc.
 Dermavant Sciences, Inc. BiotechnologyHealth Technology Part of Roivant Sciences Ltd., Dermavant Sciences, Inc. develops biological products. The company is based in Raleigh, NC. Todd Zavodnick has been the CEO of the company since 2018. | Biotechnology | Director/Board Member Chairman | |
Roivant Sciences, Inc.
 Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY. | Pharmaceuticals: Major | Corporate Officer/Principal Director/Board Member Corporate Officer/Principal Chief Executive Officer Corporate Officer/Principal President | |
Xoc Pharmaceuticals, Inc.
 Xoc Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Xoc Pharmaceuticals, Inc. operates as Biopharmaceutical Company. It focuses on the development of innovative therapeutics. The company was founded by Scott W. Borland, Miguel Guzman and Lisa Borland and is headquartered in Los Gatos, CA. | Miscellaneous Commercial Services | Director/Board Member | |
Urovant Sciences, Inc.
 Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| AKERO THERAPEUTICS, INC. | Pharmaceuticals: Major | Chief Executive Officer | |
| UROVANT SCIENCES LTD. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Genevant Sciences Corp.
 Genevant Sciences Corp. Pharmaceuticals: MajorHealth Technology Part of Roivant Sciences Ltd., Genevant Sciences Corp. operates as a Canadian biopharmaceutical company. The company is based in Burnaby, Canada. The CEO of the company is Bo Rode Hansen. | Pharmaceuticals: Major | Director/Board Member Chairman Chief Executive Officer Director/Board Member | |
Altavant Sciences, Inc.
 Altavant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Altavant Sciences, Inc. is a clinical stage biopharmaceutical company, which provides therapies that treat respiratory diseases with an initial therapeutic focus in pulmonary arterial hypertension (PAH). The company is headquartered in Cary, NC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chief Executive Officer | |
Dermavant Sciences Ltd.
 Dermavant Sciences Ltd. Pharmaceuticals: MajorHealth Technology Dermavant Sciences Ltd. is a clinical-stage biopharmaceutical company which focuses on developing and commercializing therapeutics in medical dermatology. The company is developing a pipeline of therapies in medical dermatology and is currently advancing development programs for five product candidates which targets specific unmet needs in two of the immuno-dermatology markets, psoriasis and atopic dermatitis, as well as other large markets, including vitiligo, primary focal hyperhidrosis and acne. The company was founded on September 28, 2015 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Chairman | |
Aruvant Sciences, Inc.
 Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Aruvant Sciences, Inc. operates as a clinical-stage biopharmaceutical company. The firm develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning. It's lead candidate ARU-1801, is a modified fetal hemoglobin gene therapy for sickle cell disease and related hemoglobinopathies. The company is headquartered in New York, NY. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| IMMUNOVANT, INC. | Biotechnology | Director/Board Member Chairman Director/Board Member | |
Sumitovant Biopharma, Inc.
 Sumitovant Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Sumitovant Biopharma, Inc. provides biotechnology services. It offers oncology, gene therapy, rare, pulmonary, urological disease, digital innovation and novel platforms. The company is headquartered in New York, NY. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
| VERA THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
| Armida Winery | Director of Finance/CFO |
Statistics
International
| United States | 38 |
| Canada | 6 |
| United Kingdom | 5 |
| Germany | 2 |
| Switzerland | 2 |
Sectoral
| Health Technology | 37 |
| Consumer Services | 8 |
| Commercial Services | 5 |
| Finance | 3 |
Operational
| Director/Board Member | 139 |
| Corporate Officer/Principal | 65 |
| Independent Dir/Board Member | 40 |
| Director of Finance/CFO | 30 |
| Chief Executive Officer | 29 |
Most connected contacts
| Insiders | |
|---|---|
| Myrtle Potter | 41 |
| Frank Torti | 35 |
| Daniel Burgess | 28 |
| Adam Daniel Cutler | 16 |
| Richard Henriques | 15 |
| Keith Manchester | 15 |
| Vivek Ramaswamy | 14 |
| Bruce G. Cousins | 14 |
| Eric Venker | 12 |
| John Naftzger | 12 |
| David Hastings | 12 |
| Frank Karbe | 11 |
| William T. Symonds | 11 |
| Andrew Cheng | 10 |
| Michael Sofia | 10 |
- Stock Market
- Insiders
- Karen Sims
- Company connections
